title: Fractalkine receptor is expressed in mature ovarian teratomas and required for epidermal lineage differentiation.
abstract: BACKGROUND
  The goal of this study was to determine a predominant cell type expressing fractalkine receptor (CX3CR1) in mature ovarian teratomas and to establish functional significance of its expression in cell differentiation.
  
  
  METHODS
  Specimens of ovarian teratoma and human fetal tissues were analyzed by immunohistochemistry for CX3CR1expression. Ovarian teratocarcinoma cell line PA-1 was used as a model for cell differentiation.
  
  
  RESULTS
  We found that the majority of the specimens contained CX3CR1-positive cells of epidermal lineage. Skin keratinocytes in fetal tissues were also CX3CR1- positive. PA-1 cells with downregulated CX3CR1 failed to express a skin keratinocyte marker cytokeratin 14 when cultured on Matrigel in the presence of a morphogen, bone morphogenic protein 4 (BMP-4), as compared to those expressing scrambled shRNA.
  
  
  CONCLUSIONS
  Here we demonstrate that CX3CR1 is expressed in both normally (fetal skin) and abnormally (ovarian teratoma) differentiated keratinocytes and is required for cell differentiation into epidermal lineage.
authors: Biopharmaceutical Sciences, University of Illinois at Chicago, 833 S Wood Str, Chicago, IL 60612, USA. mvb@uic.edu.
authors: Lisa
authors: L
authors: Rooper
authors: Hilal
authors: H
authors: Gurler
authors: Andre A
authors: AA
authors: Kajdacsy-Balla
authors: Maria V
authors: MV
authors: Barbolina
references: Eur J Immunol. 2011 May;41(5):1256-65
references: 21425158
references: Arch Gynecol Obstet. 2010 Nov;282(5):529-33
references: 20049468
references: Mol Cancer Res. 2010 May;8(5):653-64
references: 20460402
references: J Immunol. 2008 Jan 1;180(1):569-79
references: 18097059
references: Int J Cancer. 1980 Jan 15;25(1):19-32
references: 6931103
references: J Immunol. 2009 Dec 15;183(12):7825-31
references: 19923448
references: Mol Cancer Res. 2012 Nov;10(11):1419-29
references: 22964431
references: Cell. 1997 Nov 14;91(4):521-30
references: 9390561
references: Int J Androl. 1981 Mar;4 Suppl s4:61-77
references: 29112247
references: AJR Am J Roentgenol. 1999 Feb;172(2):445-9
references: 9930800
references: Shi Yan Sheng Wu Xue Bao. 1995 Dec;28(4):397-407
references: 8731971
references: J Natl Cancer Inst. 1974 Mar;52(3):921-30
references: 4524119
references: Proc Natl Acad Sci U S A. 1976 Feb;73(2):549-53
references: 1061157
references: Expert Opin Ther Targets. 2010 Feb;14(2):207-19
references: 20055718
references: AJR Am J Roentgenol. 2004 Sep;183(3):743-50
references: 15333365
references: Expert Opin Ther Targets. 2012 Jun;16(6):613-8
references: 22530606
references: Mol Cancer Res. 2012 Jan;10(1):11-24
references: 22064656
references: Eur J Radiol. 2009 Dec;72(3):454-63
references: 18804932
references: J Med Genet. 1984 Feb;21(1):4-12
references: 6363699
references: Radiographics. 2001 Mar-Apr;21(2):475-90
references: 11259710
references: Gynecol Oncol. 1998 Sep;70(3):418-20
references: 9790798